Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study consists of two parts: phase 2 (Part A) and phase 3 (Part B). It is a multicenter study designed to evaluate the safety, effectiveness, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD, and to evaluate the safety and tolerability of CSL889 in study participants.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
•At the time of informed consent: >= 18 years of age (adults); or >= 12 to less than (<) 18 years of age (adolescents, where approved and when enrollment for adolescents has been opened by the sponsor, with the endorsement of the Independent Data Monitoring Committee [IDMC]).
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
260 participants in 6 patient groups, including a placebo group
Loading...
Central trial contact
Trial Registration Coordinator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal